Nevro's Senza HFX iQ spinal cord stimulation was approved by the FDA for treating chronic back pain, the devicemaker said Oct. 13.
It's the first artificial intelligence-based spinal cord stimulation system that learns from patients, according to a news release. The device will launch with algorithms aimed at treating chronic back and leg pain.
"Pain is variable from patient to patient and over time," D. Keith Grossman, chair and CEO of Nevro, said in the release. "Using the big data from our HFX Cloud patient database, our unique HFX algorithm was developed to identify those programs where patients have been more likely to get relief in the real world."